CAR-T 与 CAR-NK 细胞疗法治疗卵巢癌的当前进展
Current Developments of CAR-T and CAR-NK Cell Therapies for Ovarian Cancer.
卵巢癌(OC)仍是最致命的妇科恶性肿瘤,其特征为诊断晚、肿瘤异质性和化疗耐药,导致生存率低。
44.4分
★★☆☆☆
FRONTIER PAPERS
Current Developments of CAR-T and CAR-NK Cell Therapies for Ovarian Cancer.
卵巢癌(OC)仍是最致命的妇科恶性肿瘤,其特征为诊断晚、肿瘤异质性和化疗耐药,导致生存率低。
Tumor immune microenvironmental characteristics in Human Epidermal Growth Factor-2 (HER2) positive esophageal adenocarcinoma: A comparative analysis a
HER2表达与上皮性肿瘤特征相关。HER2阳性TIME显示免疫细胞浸润减少,但免疫耗竭相关抑制信号表达也较低,这对anti-HER2药物与检查点抑制剂联合给药潜在临床获益的机制提出了疑问。由于有限应答与VEGF信号增强相关,研究可探讨靶向VEGF与HER2的潜在协同作用。
Precision Immunotherapy Utilizing Adapter CAR-T Cells (AdCAR-T) in Metastatic Breast Cancer Leads to Target Specific Lysis.
我们的结果表明,MPE来源的类器官可作为可靠工具,以患者个体化方式评估AdCAR-T对转移性BC的疗效。
共 3 条
MEMBER ACCOUNT
登录成功会直接打开下一页。